Previous 10 | Next 10 |
Rigel Pharmaceuticals ( NASDAQ: RIGL ) is eliminating 16% of its workforce -- 30 positions -- in the wake of a decision to not file supplemental New Drug Application (sNDA) for fostamatinib for warm autoimmune hemolytic anemia. Shares are down 12% in after-hou...
Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback PR Newswire --Announces Workforce Reduction-- SOUTH SAN FRANCISCO, Calif. , Oct. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced t...
STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief F...
Rigel to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Sept. 6, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief...
The shares of clinical-stage biotech Rigel Pharmaceuticals, Inc. ( NASDAQ: RIGL ) continued the recent momentum to add more than 7% at the market open on Thursday, reaching the highest level since June. Ahead of the uptick in RIGL shares, H.C. Wainwright more than doub...
Cedar Realty Trust ( CDR ) +204% . Codiak BioSciences ( CDAK ) +33% . Curis ( CRIS ) +32% Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib. Bruush Oral Care ( BRSH ) +25% . Wolfspeed ( WOLF ) +21% Q2 ear...
Rigel Pharma ( NASDAQ: RIGL ) is trading 17% higher after the company reported Q2 result that beat estimates, helped by higher sales of Tavalisse to treat adults with low platelet counts due to chronic immune thrombocytopenia. The company reported Q2 GAAP ...
The following slide deck was published by Rigel Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Rigel Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2022 Earnings Conference Call August 02, 2022, 04:30 PM ET Company Participants Dolly Vance - Executive Vice President, Corporate Affairs and General Counsel Raul Rodriguez - President and Chief Executive Officer Dave Santos ...
Rigel Pharmaceuticals press release ( NASDAQ: RIGL ): Q2 GAAP EPS of -$0.08 beats by $0.04 . Revenue of $29.82M (+13.5% Y/Y) beats by $6.17M . Shares -4% . For further details see: Rigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.04, revenue o...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
2024-06-27 09:02:05 ET Rigel Pharmaceuticals (RIGL) announced stock split at a ratio of 1-for-10 on 2024-06-27 ... Full story available on KlickAnalytics.com
Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common st...
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmac...